1 in 1,000 Privately Insured 17-Year-Olds Were Taking Cross-Sex Hormones Prior to State Bans
The authors of a new study analyzing 2018 to 2022 insurance claims data characterized such prescriptions as rare and said this rarity undermined arguments for bans of these interventions.
The video above is
Keep reading with a 7-day free trial
Subscribe to Hazard Ratio: Benjamin Ryan to keep reading this post and get 7 days of free access to the full post archives.